Bicycle Therapeutics Valuation Multiples

Bicycle Therapeutics Overview

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Founded

2009

HQ

Employees

305

Website

bicycletherapeutics.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $60M

EBITDA: ($216M)

Market Cap

$372M

Valuation Multiples

Multiples.vc

Start free trial

Bicycle Therapeutics Financials

Bicycle Therapeutics reported last 12-month revenue of $60M and negative EBITDA of ($216M).

In the same LTM period, Bicycle Therapeutics generated $60M in gross profit, ($216M) in EBITDA losses, and had net loss of ($198M).

Bicycle Therapeutics P&L

In the most recent fiscal year, Bicycle Therapeutics reported revenue of $73M and EBITDA of ($212M).

Bicycle Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics has current market cap of $372M.

Bicycle Therapeutics' stock price is $5.33.

Bicycle Therapeutics Valuation Multiples

Bicycle Therapeutics trades at (4.0x) EV/Revenue multiple, and 1.1x EV/EBITDA.

Bicycle Therapeutics Financial Valuation Multiples

As of April 18, 2026, Bicycle Therapeutics has market cap of $372M.

Equity research analysts estimate Bicycle Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bicycle Therapeutics has a P/E ratio of (1.9x).

Bicycle Therapeutics Margins & Growth Rates

Bicycle Therapeutics' revenue in the last 12 month declined by (49%).

Bicycle Therapeutics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.1M for the same period.

Bicycle Therapeutics' rule of 40 is (554%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bicycle Therapeutics' rule of X is (640%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Bicycle Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Bicycle Therapeutics M&A Activity

Bicycle Therapeutics acquired XXX companies to date.

Last acquisition by Bicycle Therapeutics was on XXXXXXXX, XXXXX. Bicycle Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bicycle Therapeutics Investment Activity

Bicycle Therapeutics invested in XXX companies to date.

Bicycle Therapeutics made its latest investment on XXXXXXXX, XXXXX. Bicycle Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).